Back to search

Article

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024

2026-05-21

Abstract excerpt

<h4>Background: </h4> Precision oncology continues to redefine cancer care by enabling promising biomarker-driven, individualized therapeutic strategies. However, concerns remain regarding and unequal global participation and advancement in precision oncology re-search especially between high-income countries (HICs) and low- and middle-income countries (LMICs). This study evaluates geographic disparities in clinic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
17c078e0-e860-559d-84df-07a117281dcc
DOI
10.20944/preprints202605.1408.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024DOI 10.20944/preprints202605.1408.v1
The Current Landscape of Clinical TrialsSemantic proximity
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologySemantic proximity
Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity
Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology TrialsSemantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation.Semantic proximity
Launch Sequencing of Pharmaceuticals with Multiple Therapeutic Indications: Evidence from Seven CountriesSemantic proximity
Evolving or Immutable - Phase I Solid Tumor Trials in the Era of Precision OncologySemantic proximity
The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of GermanySemantic proximity
Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global DisparitiesSemantic proximity
Trend Analysis of Regulatory Approval Pathways and Major Shifts in Pivotal Clinical Trial Designs for Antineoplastic Drugs Approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) From 2004 to 2019.Semantic proximity
New Benchmarks on Demographic Disparities in Pivotal Trials Supporting FDA Approved Drugs and BiologicsSemantic proximity
Select a neighboring publication to make it the new centre.